WO2014001956A3 - Combinational use of pegylated recombinant human arginase with chemotherapeutic/target therapeutic drug in cancer treatment - Google Patents

Combinational use of pegylated recombinant human arginase with chemotherapeutic/target therapeutic drug in cancer treatment Download PDF

Info

Publication number
WO2014001956A3
WO2014001956A3 PCT/IB2013/054971 IB2013054971W WO2014001956A3 WO 2014001956 A3 WO2014001956 A3 WO 2014001956A3 IB 2013054971 W IB2013054971 W IB 2013054971W WO 2014001956 A3 WO2014001956 A3 WO 2014001956A3
Authority
WO
WIPO (PCT)
Prior art keywords
chemotherapeutic
therapeutic drug
target therapeutic
recombinant human
cancer treatment
Prior art date
Application number
PCT/IB2013/054971
Other languages
French (fr)
Other versions
WO2014001956A2 (en
Inventor
Ning Man Cheng
Li Chen
Original Assignee
Ning Man Cheng
Li Chen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ning Man Cheng, Li Chen filed Critical Ning Man Cheng
Publication of WO2014001956A2 publication Critical patent/WO2014001956A2/en
Publication of WO2014001956A3 publication Critical patent/WO2014001956A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

The present invention provides a method for treatment of cancer comprising administration of an arginine reducing compound and a chemotherapeutic/target therapeutic drug to a subject in need thereof. In one embodiment, the cancer is liver cancer or prostate cancer. In another embodiment, the arginine reducing compound is pegylated recombinant human arginase and the chemotherapeutic/target therapeutic drug is oxaliplatin, everolimus, paclitaxel or sorafenib.
PCT/IB2013/054971 2012-06-25 2013-06-18 Combinational use of pegylated recombinant human arginase with chemotherapeutic/target therapeutic drug in cancer treatment WO2014001956A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261663632P 2012-06-25 2012-06-25
US61/663,632 2012-06-25

Publications (2)

Publication Number Publication Date
WO2014001956A2 WO2014001956A2 (en) 2014-01-03
WO2014001956A3 true WO2014001956A3 (en) 2014-02-20

Family

ID=49783953

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2013/054971 WO2014001956A2 (en) 2012-06-25 2013-06-18 Combinational use of pegylated recombinant human arginase with chemotherapeutic/target therapeutic drug in cancer treatment

Country Status (1)

Country Link
WO (1) WO2014001956A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106456723B (en) * 2014-04-29 2021-03-09 康达医药科技有限公司 Methods and compositions for modulating the immune system using arginase I
WO2016188799A1 (en) 2015-05-22 2016-12-01 Philips Lighting Holding B.V. Lighting control based on orientation and auxiliary device input

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1169951C (en) * 1997-05-12 2004-10-06 德西涅Rx制药公司 Modified arginine deiminase
WO2006058486A1 (en) * 2004-12-03 2006-06-08 Bio-Cancer Treatment International Limited Use of arginase in combination with 5fu and other compounds for treatment of human malignancies
WO2012012305A2 (en) * 2010-07-18 2012-01-26 Niiki Pharma Inc. Combination therapy using a ruthenium complex

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1169951C (en) * 1997-05-12 2004-10-06 德西涅Rx制药公司 Modified arginine deiminase
WO2006058486A1 (en) * 2004-12-03 2006-06-08 Bio-Cancer Treatment International Limited Use of arginase in combination with 5fu and other compounds for treatment of human malignancies
WO2012012305A2 (en) * 2010-07-18 2012-01-26 Niiki Pharma Inc. Combination therapy using a ruthenium complex

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
T. L. LAM ET AL.: "Recombinant human arginase inhibits proliferation of human hepatocellular carcinoma by inducing cell cycle arrest.", CANCER LETTERS., vol. 277, no. ISSUE, 8 May 2009 (2009-05-08), pages 91 - 100 *

Also Published As

Publication number Publication date
WO2014001956A2 (en) 2014-01-03

Similar Documents

Publication Publication Date Title
AU2018201942B2 (en) Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
WO2015031771A3 (en) Administration of kynurenine depleting enzymes for tumor therapy
WO2013177187A3 (en) Synergistic tumor treatment with extended-pk il-2 and therapeutic agents
BR112014024848A2 (en) combination therapy with an antihyaluronan agent and a tumor targeting taxane
MX2017014338A (en) Targeted selection of patients for treatment with cortistatin derivatives.
MX2020012924A (en) Treatment of cancer using coenzyme q10 combination therapies.
WO2015009726A3 (en) Medical uses of cd38 agonists
DK2790738T3 (en) BIOMARKETERS FOR COLLATERAL REINACTIVATION AND TARGETS FOR CANCER THERAPY
WO2014145642A3 (en) Nrf2 small molecule inhibitors for cancer therapy
IN2014MN02089A (en)
HK1223037A1 (en) Pharmaceutical composition comprising modified hemoglobin- based therapeutic agent for cancer targeting treatment and diagnostic imaging
HK1211979A1 (en) Pharmaceutical composition comprising albumin-binding arginine deiminase for cancer targeting treatment
PH12015502616A1 (en) Pharmaceutical combination comprising metformin and dihydroquercetin and its use for the treatment of cancer
IL226205B (en) Fusion proteins, pharmaceutical compositions comprising them and their use in the manufacture of medicaments for cancer therapy
IL237281B (en) Drug delivery systems and methods for treatment of bladder cancer comprising oxaliplatin
WO2013135602A3 (en) Combination therapy for the treatment of ovarian cancer
EP3266865A4 (en) Cell therapeutic agent for cancer treatment and combination therapy with same
EP3581653A3 (en) Methods and compositions for treating cancer using peptide nucleic acid-based agents
WO2013096335A8 (en) ADMINISTRATION OF AN ANTAGONIST OF α5β1 FOR ANTI-ANTIOGENESIS AND CANCER TREATMENT
WO2014001956A3 (en) Combinational use of pegylated recombinant human arginase with chemotherapeutic/target therapeutic drug in cancer treatment
EP2969008A4 (en) Medicament for treatment of cancer, cardiovascular diseases and inflammation
EP2836217A4 (en) Compositions and methods for treatment of the side-effects associated with administration of cancer chemotherapeutic agents
WO2012158776A3 (en) Combination therapy for treatment of cancer
EA201590325A1 (en) IMPROVED CANCER TREATMENT WITH REDUCED RENAL TOXICITY
UA88769U (en) Method for preventing and treating benign breast dysplasia in patients with early miscarriage

Legal Events

Date Code Title Description
32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 03/07/2015)

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13810479

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 13810479

Country of ref document: EP

Kind code of ref document: A2